Roche Diagnostics Australia › Health Topics › Oncology
A greater understanding of cancer biology combined with technological advancements allows us to deliver industry-leading diagnostics.
Progress in cancer treatment has been made through molecular analysis and biomarker discovery. Major breakthroughs have transformed several aspects of screening strategies and clinician care for treatment decisions. Cancer treatment has evolved from broad chemotherapy to targeted therapy and immunotherapies. Additionally, innovative technologies such as next-generation sequencing, liquid biopsies and artificial intelligence-powered image analysis algorithms are facilitating evolution in personalised healthcare. These advances have changed the natural course of disease for millions of patients.
Our long-term vision is to help prevent or cure this disease in all its forms, and our scientific rigour, the pipeline of innovative therapies and passion for progress will continue to aid in the advancement of cancer care in the years ahead.
Combining a patient-centric approach with deep business acumen in the oncology disease area, Derek has a passion for education and patient advocacy. His focus is on improving outcomes by providing integrative solutions that make a difference in the lives of patients and their families. With over 20 years of experience in the oncology space, improving the knowledge and capability of our specialist physicians, GPs, Nurses and Pharmacists is a focus for Derek in his role as Oncology Disease Area Lead at Roche Diagnostics Australia.
Precision Oncology Screening Platform Enabling Clinical Trials
Roche Australia, in partnership with the Australian Federal Government, Omico, and other partners, has announced an agreement to jointly fund an important new initiative aimed at improving access to clinical trials for Australians diagnosed with cancer.
Australia One of First to Offer Game-Changing Self-Collection Option For Cervical Cancer Screening
From 1st July all Australian women aged 25 to 74 years of age will be among the first in the world to have the option to take a self-collected – a move that is expected to increase screening participation rates to help eliminate cervical cancer by 2030.
Lung cancer patient 'going for the cure'
In 2016, Amanda, a non-smoker and diligent about health and fitness, was diagnosed with stage IV lung cancer.
The Liver Foundation
Roche Diagnostics Australia was fortunate to host two very special guests; Richard Wylie, CEO The Liver Foundation and Nick Cole, Liver Cancer Patient Advocate. Nick and Richard gave a heart wrenching yet inspiring presentation to the 100+ Roche Diagnostics employees, highlighting the importance of early screening and taking preventative action.
#MoveYourRDAss
To raise vital awareness and funds for the Liver Foundation, employees of Roche Diagnostics Australia (RDA) completed a whopping combined 566,102KM virtual workout journey around Australia! Now that each team has completed their goal of 15,000 virtual KMs, RDA will be donating $15,000 to The Liver Foundation.
Take a look back at our #MoveYourRDAss virtual journey!
Rare Cancers Australia
Roche Diagnostics Australia had the privilege of hosting chairman and founder of Rare cancers Australia, Richard Vines and Rare Cancer Patient Advocate, Dr Lisa Briggs to discuss the importance of personalised and targeted healthcare for Rare Cancers.
This page is provided as a contact service and does not replace the advice of a physician. Roche cannot respond to questions about general medical information or questions regarding your personal medical condition. Medications and diagnostics products can not be directly ordered through this website. Please note that we do not respond to form letters or e-mail campaigns.
09441751001_00000000_02
